Posted by Michael Wonder on 08 Apr 2019
Pazdur on pandemonium: calls for collaboration, competition on PD-1 drugs
8 April 2019 - Pazdur chastises PD-1/PD-L1 pharmas for losing sight of patients.
In separate sessions at AACR, FDA’s Oncology chief Richard Pazdur’s pointed comments and questions to PD-1/PD-L1 companies made it clear that he thinks patients are getting hurt from pharmas’ failure to collaborate and the high drug prices they’re demanding.
At the American Association for Cancer Research meeting, the Oncology Center of Excellence Director called on Western companies to collaborate on platform trials and encouraged Chinese companies to compete in the U.S. on price.
